bpc-157 human clinical trial musculoskeletal injury The “Wolverine” Drug – Ortho Rhode Island What no one's telling you
Description
Its pretty locally acting, and I would use it on just about anybody
In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, i.e., its evidence to establish safety for human use is currently insufficient
How do I safely dilute glacial acetic acid
Its also a precursor to both methylcobalamin and adenosylcobalamin
A key benefit is that this part of the thigh generally has fewer nerve endings, which often means less discomfort during the injection
doi: 10.1128/JVI.79.12.7819-7826.2005 50 SpinettiGBernardiniGCamardaGMangoniASantoniACapogrossiMCet al
